Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YOSAFE TEMESGEN WAKWAYA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1205275336
CMS profile
426088
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,196.51

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,115.65 52
Education $80.86 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 53 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YOSAFE TEMESGEN WAKWAYA

NPI 1205275336 · CMS profile ID 426088

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 53 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 53 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 53 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 53 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1205275336?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $1,196.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $21.9112/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089569077 CMS
ANI Pharmaceuticals, Inc. $20.4612/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091149382 CMS
GENZYME CORPORATION $25.3712/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139954144 CMS
GlaxoSmithKline, LLC. $25.6312/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116013323 CMS
GlaxoSmithKline, LLC. $20.8411/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116255352 CMS
Vifor Pharma, Inc. $25.3811/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124059566 CMS
Regeneron Healthcare Solutions, Inc. $36.3911/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114242032 CMS
Grifols USA, LLC $22.6311/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124756388 CMS
Insmed, Inc. $26.9711/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089572304 CMS
Regeneron Healthcare Solutions, Inc. $26.4710/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114242026 CMS
Merck Sharp & Dohme LLC $16.2410/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141827298 CMS
GlaxoSmithKline, LLC. $18.7010/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116161441 CMS
GlaxoSmithKline, LLC. $0.4310/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116643032 CMS
ANI Pharmaceuticals, Inc. $20.4710/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091156010 CMS
SCPHARMACEUTICALS INC. $13.3310/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132304041 CMS
Alafair Biosciences, Inc. $25.3910/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138674768 CMS
AstraZeneca Pharmaceuticals LP $14.5910/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104374869 CMS
AstraZeneca Pharmaceuticals LP $22.4409/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105814029 CMS
Regeneron Healthcare Solutions, Inc. $28.1009/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114242020 CMS
GlaxoSmithKline, LLC. $20.8409/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116022810 CMS
Insmed, Inc. $27.9109/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089557414 CMS
AstraZeneca Pharmaceuticals LP $14.2509/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104395017 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.9609/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117914139 CMS
Regeneron Healthcare Solutions, Inc. $28.8708/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114242014 CMS
Insmed, Inc. $23.5608/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089567935 CMS
AstraZeneca Pharmaceuticals LP $15.5408/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104542912 CMS
GlaxoSmithKline, LLC. $17.6307/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116436087 CMS
GlaxoSmithKline, LLC. $20.8407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116260406 CMS
Vifor Pharma, Inc. $21.8807/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124049672 CMS
Regeneron Healthcare Solutions, Inc. $26.9507/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114242007 CMS
AstraZeneca Pharmaceuticals LP $18.5907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105890848 CMS
Amgen Inc. $16.5107/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116198401 CMS
Merck Sharp & Dohme LLC $18.2906/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141573901 CMS
AstraZeneca Pharmaceuticals LP $15.5406/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104495458 CMS
Regeneron Healthcare Solutions, Inc. $80.8606/18/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114242000 CMS
Regeneron Healthcare Solutions, Inc. $28.6905/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114241994 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.4605/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117914141 CMS
Insmed, Inc. $25.9104/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089573948 CMS
Regeneron Healthcare Solutions, Inc. $35.4404/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114241988 CMS
GlaxoSmithKline, LLC. $12.8004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116637270 CMS
Merck Sharp & Dohme LLC $18.4504/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141573903 CMS
Vifor Pharma, Inc. $24.1004/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124047121 CMS
Regeneron Healthcare Solutions, Inc. $37.1203/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114241982 CMS
AstraZeneca Pharmaceuticals LP $21.4403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105898954 CMS
AstraZeneca Pharmaceuticals LP $13.9103/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104690862 CMS
GlaxoSmithKline, LLC. $11.4603/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116720626 CMS
Insmed, Inc. $27.8703/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089573386 CMS
GlaxoSmithKline, LLC. $12.7903/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116532936 CMS
GENZYME CORPORATION $36.4902/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139954072 CMS
Itamar Medical Inc $20.8302/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153392532 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $107.72 5
PY2022 $116.96 6
PY2023 $11,034.61 30
PY2024 $1,196.51 53
PY2025 $1,564.25 70

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $164,888.09 66
PY2024 Principal investigator $189,324.86 55
PY2023 Principal investigator $66,320.20 20
PY2022 Principal investigator $4,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $260.00 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622576
Principal investigator 1 United Therapeutics Corporation $336.75 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622578
Principal investigator 1 United Therapeutics Corporation $1,122.51 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622582
Principal investigator 1 United Therapeutics Corporation $1,913.60 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622586
Principal investigator 1 United Therapeutics Corporation $2,496.00 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622592
Principal investigator 1 United Therapeutics Corporation $6,496.10 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622600
Principal investigator 1 United Therapeutics Corporation $2,496.00 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622614
Principal investigator 1 United Therapeutics Corporation $2,300.00 12/06/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622560
Principal investigator 1 United Therapeutics Corporation $1,000.00 11/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622580
Principal investigator 1 United Therapeutics Corporation $1,830.40 11/26/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622602
Principal investigator 1 United Therapeutics Corporation $2,300.00 11/13/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622610
Principal investigator 1 United Therapeutics Corporation $130.00 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622574
Principal investigator 1 United Therapeutics Corporation $2,080.00 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622590
Principal investigator 1 United Therapeutics Corporation $5,718.70 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622598
Principal investigator 1 United Therapeutics Corporation $2,080.00 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622606
Principal investigator 1 United Therapeutics Corporation $5,436.60 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622622
Principal investigator 1 United Therapeutics Corporation $1,750.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622554
Principal investigator 1 United Therapeutics Corporation $1,750.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622556
Principal investigator 1 United Therapeutics Corporation $1,950.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622558
Principal investigator 1 United Therapeutics Corporation $2,958.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622562
Principal investigator 1 United Therapeutics Corporation $8,600.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622564
Principal investigator 1 United Therapeutics Corporation $16,900.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622566
Principal investigator 1 United Therapeutics Corporation $130.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622572
Principal investigator 1 United Therapeutics Corporation $1,996.80 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622588
Principal investigator 1 United Therapeutics Corporation $4,900.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622620
Principal investigator 1 United Therapeutics Corporation $1,260.00 09/25/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622584
Principal investigator 1 United Therapeutics Corporation $5,135.00 09/25/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622596
Principal investigator 1 United Therapeutics Corporation $1,996.80 09/25/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622604
Principal investigator 1 United Therapeutics Corporation $2,300.00 09/18/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622568
Principal investigator 1 United Therapeutics Corporation $2,329.60 08/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622612
Principal investigator 1 United Therapeutics Corporation $3,919.50 08/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622618
Principal investigator 1 United Therapeutics Corporation $2,828.80 08/08/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622594
Principal investigator 1 United Therapeutics Corporation $2,300.00 08/08/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622608
Principal investigator 1 United Therapeutics Corporation $2,828.80 07/31/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622616
Principal investigator 1 United Therapeutics Corporation $130.00 07/10/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622570
Principal investigator 1 United Therapeutics Corporation $1,000.00 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622630
Principal investigator 1 United Therapeutics Corporation $2,246.40 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622638
Principal investigator 1 United Therapeutics Corporation $2,300.00 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622644
Principal investigator 1 United Therapeutics Corporation $10,574.00 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622658
Principal investigator 1 United Therapeutics Corporation $14,643.20 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622662
Principal investigator 1 United Therapeutics Corporation $2,300.00 06/12/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622642
Principal investigator 1 United Therapeutics Corporation $130.00 05/22/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622626
Principal investigator 1 United Therapeutics Corporation $2,382.90 05/22/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622646
Principal investigator 1 United Therapeutics Corporation $2,382.90 05/22/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622648
Principal investigator 1 United Therapeutics Corporation $260.00 05/08/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622628
Principal investigator 1 United Therapeutics Corporation $2,876.00 05/08/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622650
Principal investigator 1 United Therapeutics Corporation $10,341.50 04/10/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622656
Principal investigator 1 United Therapeutics Corporation $130.00 03/27/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622624
Principal investigator 1 United Therapeutics Corporation $1,929.00 03/27/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622636
Principal investigator 1 United Therapeutics Corporation $7,900.00 03/13/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622654
Principal investigator 1 United Therapeutics Corporation $1,664.00 02/28/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622632
Principal investigator 1 United Therapeutics Corporation $2,300.00 02/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622640
Principal investigator 1 United Therapeutics Corporation $11,466.00 02/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622660
Principal investigator 1 United Therapeutics Corporation $1,780.00 01/31/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622634
Principal investigator 1 United Therapeutics Corporation $6,759.00 01/31/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622652